Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).

The team has developed synthetic 'DNA switches' that can control genes in certain cells. It's believed the technology could ...

Months after disclosing significant layoffs across its North Carolina operations, Pfizer (NYSE: PFE) plans to eliminate more ...

Researchers used AI to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types.

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

Researchers at The Jackson Laboratory (JAX), the Broad Institute of MIT and Harvard, and Yale University, have used ...

The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...

Ocuphire Pharma has announced the acquisition of Opus Genetics to develop gene therapies for inherited retinal diseases (IRDs ...

RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...